GGrantIndex
← Leaderboards

Steven L Batki

University Of California San Francisco

Google Scholar ↗PubMed ↗ORCID ↗
$8,802,367
Attributed
$11,304,485
Total exposure
8
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.4M · FY2005–21
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

NIH$11,304,485 · 8

By mechanism

R01$10,035,552 · 5
R44$910,489 · 1
P50$358,444 · 1
M01$0 · 1

Top collaborators

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Methamphetamine”

Research focus

MethamphetamineClinical ResearchHuman SubjectBehavior TherapyPlacebosUrineParticipantRandomizedPharmaceutical PreparationsAmphetaminesBehavioral /Social Science Research TagSafetyHuman Therapy EvaluationOutcomes ResearchDouble-Blind MethodPharmacotherapyEnrollmentInterviewAids PreventionAnal SexComputer AssistedMen Who Have Sex With MenClinical Trial Phase IHigh Risk

Grant awards (30)

Non-Invasive Neuromodulation Device for the Treatment of Alcohol Use Disorder$910,489
R44 · FY2021 · AA
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$406,960
R01 · FY2017 · DA
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$467,860
R01 · FY2016 · DA
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$228,809
R01 · FY2016 · DA
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$524,718
R01 · FY2015 · DA
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$466,296
R01 · FY2015 · DA
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$550,847
R01 · FY2014 · DA
Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r$473,397
R01 · FY2014 · DA
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$531,920
R01 · FY2013 · DA
Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B$442,940
R01 · FY2011 · DA
Improving Hepatitis C Treatment in Injection Drug Users$505,180
R01 · FY2007 · DA · contact PI
Improving Hepatitis C Treatment in Injection Drug Users$748,895
R01 · FY2006 · DA · contact PI
Naltrexone Treatment of Alcohol Abuse in Schizophrenia$403,487
R01 · FY2006 · AA · contact PI
Improving Hepatitis C Treatment in Injection Drug Users$861,193
R01 · FY2005 · DA
Naltrexone Treatment of Alcohol Abuse in Schizophrenia$553,042
R01 · FY2005 · AA
Improving Hepatitis C Treatment in Injection Drug Users$818,555
R01 · FY2004 · DA
Naltrexone Treatment of Alcohol Abuse in Schizophrenia$566,377
R01 · FY2004 · AA
Improving Hepatitis C Treatment in Injection Drug Users$612,502
R01 · FY2003 · DA
Naltrexone Treatment of Alcohol Abuse in Schizophrenia$585,612
R01 · FY2003 · AA
INCENTIVES TO IMPROVE TREATMENT OUTCOME IN HIV AND IDUS$179,222
P50 · FY2002 · DA
PHARMACOTHERAPY OF METHAMPHETAMINE DEPENDENCE$22,050
R01 · FY2002 · DA
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2002 · RR
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2002 · RR
INCENTIVES TO IMPROVE TREATMENT OUTCOME IN HIV AND IDUS$179,222
P50 · FY2001 · DA
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2001 · RR
PHARMACOTHERAPY OF METHAMPHETAMINE DEPENDENCE$264,912
R01 · FY2000 · DA
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2000 · RR
INCENTIVES TO IMPROVE TREATMENT OUTCOME IN HIV AND IDUS$0
P50 · FY2000 · DA
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2000 · RR
METHAMPHETAMINE AND AMLODIPINE INTERACTIONS$0
M01 · FY2000 · RR